Another fantastic result, that opens another dimension for Clarity's diagnostic suite.
AT: "Copper-64 has comparably low radiation doses to currently used isotopes and involves similar management of patients. However, the longer half-life of copper-64 of 12.7 hours, combined with Clarity’s proprietary position in copper-based theranostics, now sets up a foundation for a complete suite of next-generation radiodiagnostics, which could be unmatched in the radiopharmaceutical sector. The opportunity for centralised, multi-layer manufacturing and broad distribution means that every patient with access to PET imaging can potentially have optimal cancer diagnostic care, not limited by isotope half-life."
- Forums
- ASX - By Stock
- CU6
- Ann: Last patient assessment completed for SARTATE trial
CU6
clarity pharmaceuticals ltd
Add to My Watchlist
2.43%
!
$4.21

Ann: Last patient assessment completed for SARTATE trial, page-2
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
$4.21 |
Change
0.100(2.43%) |
Mkt cap ! $1.369B |
Open | High | Low | Value | Volume |
$4.46 | $4.62 | $4.20 | $29.97M | 6.888M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
9 | 4387 | $4.21 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$4.25 | 3196 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
9 | 4387 | 4.210 |
20 | 71549 | 4.200 |
2 | 7165 | 4.190 |
1 | 2403 | 4.180 |
2 | 9301 | 4.170 |
Price($) | Vol. | No. |
---|---|---|
4.250 | 3196 | 2 |
4.260 | 2035 | 1 |
4.270 | 11092 | 4 |
4.300 | 35227 | 1 |
4.310 | 1000 | 1 |
Last trade - 16.10pm 28/07/2025 (20 minute delay) ? |
Featured News
CU6 (ASX) Chart |
The Watchlist
P.HOTC
HotCopper
Frazer Bourchier, Director, President and CEO
Frazer Bourchier
Director, President and CEO
SPONSORED BY The Market Online